Skip to main content

A miniature Bio-photonics Companion Diagnostics platform for reliable cancer diagnosis and treatment monitoring.

Objective

Current diagnostic options for cancer treatment monitoring rely on imaging techniques and cannot guarantee proper assessment of therapeutic response. This project aims to develop a disruptive Point of Care (PoC) device for cancer early diagnosis and treatment monitoring as a companion diagnostics tool. One of the scientific breakthroughs of this project is the development of a “cancer stem cells” detection platform by virtue of expression of the cancer stem cell-specific transcription factor TWIST1, which controls the expression of the bloodstream circulating biomarkers POSTN, PCOLCE and TGBI. Cancer stem cells represent the most aggressive/tumorigenic cell compartment within tumors.
BIOCDx will combine advanced concepts from the photonic, nano-biochemical, micro-fluidic and reader/packaging platforms aiming to overcome limitations related to detection reliability, sensitivity, specificity, compactness and cost issues. BIOCDx will rely on ultrasensitive, photonic elements based on an array of 8 asymmetric MZI waveguides fabricated by TriPlex technology on silicon nitride substrates and will achieve a 100 fold improvement –with respect to current technologies- of sensitivity (<10-8 RIU). BIOCDx will emlploy a smart concept of signal multiplexing for lowering the number of photodetectors required in multi-analyte detection and allowing for a substantial reduction of chip size. A sandwich assay, enhanced with nanoparticles, will be developed, based on the use of two antibodies per protein, to detect all three circulating proteins. This will enhance the limit of detection (LOD) close to femtomolar and the reliability. BIOCDx photonic, nano-biochemical, fluidics and packaging platforms will be integrated into a portable, desktop PoC device. Its validation in preclinical and clinical setting will be performed in three cancer types: breast cancer, hormone-independent prostate cancer and melanoma.

Call for proposal

H2020-ICT-2016-1
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS
Address
Patission Str. 42
10682 Athina
Greece
Activity type
Research Organisations
EU contribution
€ 700 985

Participants (6)

LIONIX INTERNATIONAL BV
Netherlands
EU contribution
€ 559 500
Address
Hengelosestraat 500
7521 AN Enschede
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LRE MEDICAL GMBH
Germany
EU contribution
€ 710 000
Address
Hofer Strasse 5
86720 Nordlingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT
Switzerland
EU contribution
€ 0
Address
Rue Jaquet Droz 1
2000 Neuchatel
Activity type
Research Organisations
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU contribution
€ 550 125
Address
Soranou Efesiou 4
115 27 Athina
Activity type
Research Organisations
FUTURE DIAGNOSTICS SOLUTIONS BV
Netherlands
EU contribution
€ 328 125
Address
Nieuweweg 279
6603 BN Wijchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LEAD PHARMA HOLDING BV
Netherlands
EU contribution
€ 315 000
Address
Kloosterstraat 9
5349 AB Oss
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)